MedPath
NMPA Approval

MabThera sc

国药准字SJ20240013

April 2, 2024

Drug Information

利妥昔单抗注射液(皮下注射)

注射剂

1400mg(11.7ml)/瓶

生物制品

April 2, 2024

April 1, 2029

Company Information

Applicant Company

Grenzacherstrasse 124, 4058 Basel, Switzerland

Manufacturing Company

Wurmisweg, 4303 Kaiseraugst, Switzerland

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

利妥昔单抗注射液(皮下注射) - NMPA 批准文号 | MedPath